2023肝細(xì)胞癌流行病學(xué)全球趨勢：篩查、預(yù)防和治療的啟示

從病毒相關(guān)性肝病患者向非病毒性病因(包括酒精相關(guān)和代謝功能障礙相關(guān)的脂肪性肝病)導(dǎo)致的患者轉(zhuǎn)變。這對Age-standardizodincidencerateper100.000indiwiduslsAge-standardizodincidencerateper100.000indiwiduslsa、1990年至2020年的年齡標(biāo)準(zhǔn)化發(fā)病率，按地理區(qū)域分層bBox1HCC主要預(yù)防尚未滿足的需求繼續(xù)研究開發(fā)HCV疫苗以及治愈(而非抑制)HBV的治療方案。variousantioxidants,withinhibAspirinAnti-inflammatoryandanti-plateleeffectsStatinsInhibitoryeffectsActivationofAMPK,whichcanOR0.AMPK,5'-adenosinemonophosphate-activcarcinoma;mTOR,mechanistictargetofrapamycin;OR,od準(zhǔn)確的風(fēng)險分層工具,用于區(qū)分高風(fēng)險個體(需要進(jìn)行肝細(xì)胞癌(HCC)監(jiān)測)和低風(fēng)險個體(可以避免監(jiān)測無用)。高度敏感的篩查工具，能夠在早期階段檢測到HCC。具有足夠特異性的篩查工具，可減少與假陽性或不確定性Non-contrastabbreviatedMRIIISmallpHCC:79%and98%,respectivelMRIvsUSalone;NCTO5095714)Contrast(gadoxeticanon-HBV-relatedcirrhSensitivityandspecificityforBCLCstageAHCC:86%and97%,respectively"Two-phaseLDCTPhaseIVHCC:83%and96%,respectivSensitivityandspeMethylatedDNAmarkersPhHCC;82%and87%,respectivMulti-cancerdetectionSmall-cohortcase-controlscomputedtomography;:US,ultrasonogsurgicalresectionorLvertSingletumour(median-3cm)(refAtezolizumab+bevacizumFirst-LinetreatmentforpatiantswithoontraindicFirstinetreatmantinChinaCamre·0CuCtmdtestilA0NA0NC從HwhrtkefgattuntatrslaNomEQ\*jc3\*hps12\o\al(\s\up1(Fmta),wcon)dNNiQlumab+lelnu=blerpaturtssthser